Competition & Markets Authority
CMA helps NHS secure price and supply commitment for cancer drugs
The CMA has worked to ensure that pharmaceutical company Aspen’s commitments to reduce prices for life-saving cancer medicines can be enforced in the UK following its exit from the European Union.
The European Commission opened an investigation into Aspen in 2017 to investigate concerns that the company had engaged in excessive pricing for 6 off-patent cancer medicines. Last year the European Commission accepted commitments by Aspen to reduce prices for the 6 medicines to address these concerns.
As a result, Aspen reduced its prices across Europe - including in the UK - by an average of approximately 73%. In addition, Aspen guaranteed the supply of the 6 cancer medicines for a period of 5 years, and, for an additional 5-year period, will either continue to supply or make its marketing authorisation available to other suppliers. This means that over the 10-year period, Aspen cannot charge more than the price set out in the commitments.
Although these commitments were offered while the UK was a part of the European Union, the commitments became legally binding under EU law after the UK was no longer part of the EU.
The CMA has now assisted the NHS to secure binding undertakings from Aspen, under the law of England and Wales, which enshrine the UK elements of the commitments and are enforceable by UK courts, including in relation to the supply of these drugs in Northern Ireland and Scotland. This means that the NHS will have effective mechanisms to monitor and ensure compliance by Aspen following the UK’s exit from the EU.
Original article link: https://www.gov.uk/government/news/cma-helps-nhs-secure-price-and-supply-commitment-for-cancer-drugs
Latest News from
Competition & Markets Authority
CMA narrows scope of concerns in Microsoft – Activision review24/03/2023 15:25:00
The CMA has today issued updated provisional findings in its assessment of Microsoft’s proposed acquisition of Activision.
Tech deal could make computer servers more expensive for UK businesses22/03/2023 16:05:00
Broadcom’s deal to buy VMware could lead to less innovation and drive up the cost of computer parts and software used by government, banks and telecoms.
First major reports on UK Internal Market published22/03/2023 13:05:00
The OIM has published its first annual and periodic reports on the UK internal market. This is the first time a systematic review of the internal market has been undertaken since the UK left the EU.
Healthcare deal could lead to higher costs for NHS17/03/2023 12:10:00
Deal to combine healthcare tech and data specialists could lead to lower quality and more expensive software options for the NHS.
Supermarket petrol station merger could increase prices for motorists and shoppers14/03/2023 12:05:00
CMA investigation finds Asda’s purchase of 132 petrol stations and attached grocery stores from the Co-op could mean higher prices or less choice for motorists or shoppers in 13 areas.
CMA launches investigation into fragrances and fragrance ingredients08/03/2023 09:10:00
The CMA has launched an investigation into suspected anti-competitive conduct in relation to the supply of fragrances and fragrance ingredients.
Merger could mean costlier and lower quality inspections for food industry07/03/2023 10:25:00
CMA’s investigation into Eville & Jones’ acquisition of Vorenta has raised competition concerns in the provision of various veterinary public health inspections.
CMA provisionally clears satellite comms deal following in-depth review01/03/2023 11:25:00
The decision comes after a Phase 2 review revealed Viasat and Inmarsat will likely face significant competition from both emerging and established players as the sector expands.